Array BioPharma (ARRY) Shares are Up 1.61%

Array BioPharma (ARRY) : Traders are bullish on Array BioPharma (ARRY) as it has outperformed the S&P 500 by a wide margin of 9.47% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.07%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.61% in the last 1 week, and is up 7.25% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 0.58% and the 50-Day Moving Average is 4.73%.The 200 Day SMA reached 2.96% Array BioPharma Inc. is up 6.92% in the last 3-month period. Year-to-Date the stock performance stands at -17.65%.


Array BioPharma (ARRY) : 6 Wall Street analysts covering Array BioPharma (ARRY) believe that the average level the stock could reach for the short term is $8. The maximum price target given is $13 and the minimum target for short term is around $6, hence the standard deviation is calculated at $2.53.

For the current week, the company shares have a recommendation consensus of Buy. Array BioPharma (NASDAQ:ARRY): stock was range-bound between the intraday low of $3.45 and the intraday high of $3.55 after having opened at $3.52 on Fridays session. The stock finally closed in the red at $3.52, a loss of -1.00%. The stock remained in the red for the whole trading day. The total traded volume was 3,549,373 shares. The stock failed to cross $3.55 in Fridays trading. The stocks closing price on Thursday was $3.475.

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer. The Companys wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition, the Company has 11 ongoing partner-funded clinical programs, including two MEK inhibitors, which are both in Phase III clinical trials, binimetinib with Novartis and selumetinib with AstraZeneca.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *